2021 European PRRS Research Award winners announced

Ingelheim, Germany, September 23, 2021 – Boehringer Ingelheim, a global leader in animal health, honors three research proposals with a total funding of 75,000 euro (25,000 euro each) to encourage further development of practical methods for controlling PRRS (Porcine Reproductive and Respiratory Syndrome), and to recognize scientific accomplishments in this field.

The independent European PRRS Research Award review board is chaired by Enric Mateu (Universidad Autònoma de Barcelona) with members from across swine practice and academia: Helle Jessen (Danvet), Andrea Ladinig (Vetmeduni Vienna), Giovanbattista Danilo Guadagnini (PigVet), Gyula Balka (Veterinary Medicine Budapest), Michele Drigo (University of Padova), and Torsten Pabst (Tierarztpraxis Dr. Pabst).

After careful evaluation the review board has selected the following winners:

• Comparison of PRRSV-1 detection by qRT-PCR in tongue fluids, processing fluids, and serum samples (Sophie Dürlinger – Vetmeduni Vienna, Austria)
   
• First field evaluation of an innovative tool for systematic PRRSV control – including a modified Holtkamp system – on farms under Western European circumstances (Karien Koenders, Eric van Esch – Lintjeshof and Merefelt Livestock Diagnostics, the Netherlands)
   
• Managing the PRRS positive sow herd – breeding stock introduction and biosecurity (Hanne Bak, Gitte Drejer – Danvet, Denmark)

“This European PRRS Research Award really makes a difference as it brings the scientific world and swine practitioners together to decide on the funding of the three most important projects, answering the burning questions related to PRRS in the field,” shared Marius Kunze, Senior Global Technical Service Manager Swine, responsible for the Award.

In 2021, Boehringer Ingelheim has sponsored the annual European PRRS Research Award for the eighth time, already has funded a total of 600,000 euro for practical research projects.

For more information please visit: www.prrs.com

Boehringer Ingelheim Animal Health

The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 9,700 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.

Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.

Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of 4.1 billion euros in 2020 and presence in more than 150 countries. For more information visit www.boehringer-ingelheim.com/animal-health

Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.